The Latest Updates from ReSPECT Clinical Trials

CNSide at SNO 2024 – CSF Assay

Plus Therapeutics to Present Groundbreaking Data on CNSide™ Cerebrospinal Fluid Assay at SNO Annual Meeting in Houston Plus Therapeutics is excited to present new findings at the Society for Neuro-Oncology (SNO) Annual Meeting in Houston, focusing on our CNSide™...

read more

Lung Cancer Awareness Month 2024

Early Detection Saves Lives: Lung Cancer and Leptomeningeal Metastases Awareness Did you know that early detection of metastatic lung cancer can improve survival rates? This Lung Cancer Awareness Month, let’s take the opportunity to educate ourselves about the...

read more

JOIN US: SNO Annual 2024

Join Plus Therapeutics at the SNO Annual Meeting in Houston! Are you attending the 2025 Society for Neuro-Oncology (SNO) Annual Meeting in Houston this week? So are we! Plus Therapeutics is excited to showcase our latest research, symposium, oral presentations, and...

read more

RECAP: ABTA NYC Race with Plus Therapeutics

Plus Therapeutics at the ABTA Race in New York: Supporting Brain Cancer Awareness and Education Check out this photo of our dedicated patient advocacy team at the @the_ABTA race in New York last weekend! The Plus Therapeutics team was proud to support and participate...

read more

Listen Now: Q3 2024 Conference Call

ICYMI: Watch the Plus Therapeutics Q3 2024 Conference Call Webcast Replay Catch up on the latest financial results and updates from Plus Therapeutics! If you missed yesterday's conference call, don't worry – you can still access the webcast replay to hear about Plus...

read more

JOIN US: ABTA 5K for Recurrent Glioblastoma

Join Plus Therapeutics at the Upcoming 5K Event in New York! Meet Our Patient Advocacy Team Speaking about ReSPECT-GBM and Recurrent Glioblastoma Don’t miss the chance to visit the Plus Therapeutics booth at the ABTA NYC community 5K next week in New York! We’re...

read more

Leptomeningeal Metastases Symposium at SNO

You're Invited: Symposium on Novel Targeted Radiotherapies for Leptomeningeal Metastases at the 2025 Society for Neuro-Oncology Annual Meeting in Houston Join Us at the SNO Annual Conference to Explore Groundbreaking Advances in Leptomeningeal Metastasis Treatment...

read more

SpectronRx Partnership

BREAKING NEWS: Plus Therapeutics and SpectronRx Announce Radiotherapeutic Manufacturing Partnership Partnership will expand Plus’ capability to meet late-stage clinical and commercial forecasts for Rhenium (186Re) Obisbemeda and reinforce supply chain redundancy Press...

read more

ICYMI GBMRO Summit

What a great glioblastoma patient summit hosted by @glioblastomaresearch🎗️🧠 We extend our heartfelt thanks to the organization for hosting this event, as well as to all the patients and caregivers who stopped by our booth and came to Dr. Brenner's presentation to...

read more

GBMRO Summit Booth

Come by our booth this weekend at @glioblastomaresearch Glioblastoma Summit in Miami; also featuring a presentation by Dr. Andrew Brenner, MD, PhD on Saturday! Our clinical and patient advocacy team will be on-site to share educational material and answer your...

read more

ABTA 5K NYC

Come join us at the upcoming @the_abta 5K run in New York City! It’s not too late to register as we join together in the fight against brain cancer. Plus Therapeutics is proud to be a sponsor and will have a booth on-site to provide education about our clinical...

read more

SNO 2024 Announcement

Mark your calendars: We will be showcasing our Leptomeningeal Metastases programs at the 2024 SNO Annual Meeting in Houston, Texas! Plus Therapeutics will present data from the ReSPECT-LM Phase 1 clinical trial of Rhenium (186Re) Obisbemeda for leptomeningeal...

read more

GBMRO Summit Announcement

Join us at the upcoming @glioblastomaresearch Glioblastoma Patient Summit as Plus Therapeutics takes the stage! The summit will be held November 1-3 in Miami, FL, and include panel talks from neurosurgeons and neuro-oncologists as well as an opportunity to connect...

read more

ICYMI CNS 2024

#ICYMI Plus Therapeutics exhibited at the #CNS2024 Annual Meeting and Dr. John Floyd presented a ReSPECT-GBM clinical trial update Key Highlights:...

read more

LM Patient Testimonial Announcement

COMING SOON 🎗️💓 In honor of #BreastCancerAwarenessMonth, we are excited to announce that we will be sharing a patient testimonial from one of our Metastatic Breast Cancer patients who was treated for Leptomeningeal Metastases through the ReSPECT-LM Clinical Trial. She...

read more

ReSPECT-GBM Update at CNS

Plus Therapeutics presented an update on the ongoing ReSPECT-GBM Phase 1/2 clinical trial, evaluating Rhenium (186Re) Obisbemeda for the treatment of recurrent glioblastoma at the 2024 Congress of Neurological Surgeons (CNS) Annual Meeting yesterday. Key...

read more

CNS 2024

Reminder to come by Plus Therapeutics at the @CNS_update 2024 Annual Meeting at Booth #2038 Plus Therapeutics is a clinical-stage pharmaceutical company developing targeted radiotherapeutics for difficult-to-treat cancers of the central nervous system with the...

read more

#WorldCancerResearchDay

Today is #WorldCancerResearchDay! Join us in celebrating the incredible advancements in cancer research and the dedicated researchers working tirelessly to find new treatments and cures. Every breakthrough brings us one step closer to a cancer-free future🔬🌟🎗️ Learn...

read more

Happy Anniversary!

Cheers to our amazing team members at Plus Therapeutics who are celebrating their work anniversaries this last quarter! Your hard work and dedication make all the difference. Here’s to many more achievements together! 🌟 https://www.instagram.com/p/DARg_EcvLxu/

read more

Texas 5Ks

Don't forget to come by the Plus Therapeutics booth at these upcoming community events next week in Texas! Our patient advocacy team can't wait to meet you. 🎗️🧠 https://give.headforthecure.org/event/head-for-the-cure-5k-san-antonio-2024/e544230...

read more